Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Elkhorn S&P 500 Capital Expenditures Portfolio (CAPX) Receives William F. Sharpe Achievement Award for ETF Innovation of the Year

12/18/2015 | 10:32am EDT

WHEATON, IL--(Marketwired - Dec 18, 2015) - Elkhorn Capital Group, LLC (BATS: ELKU), a pioneer of research-based investing and a strategic partner of Barclays, announced today the Elkhorn S&P 500 Capital Expenditures Portfolio (NASDAQ: CAPX) received the William F. Sharpe Achievement Award for ETF Innovation of the Year.

"We are proud to be recognized as innovators in the ETF industry," said Ben Fulton, Founder and CEO of Elkhorn Investments. "CAPX is the only capital expenditures-focused ETF available today, providing investors access to S&P 500 companies that are efficiently reinvesting back into their business to drive future growth. Historically, capex strategies have offered investors exposure to companies with strong performance later in the economic cycle as well as in rising rate environments."

The Elkhorn S&P 500 Capital Expenditures Portfolio seeks to track the performance of the S&P 500 Capex Efficiency Index, which is designed to provide exposure to 100 constituents of the S&P 500 that have exhibited strong capital discipline in the form of efficient capital expenditures. The Index focuses on capex efficiency, not just capex spending levels, providing exposure to companies that have maximized sales per unit of capital expenditures.

The William F. Sharpe Awards recognize the best and the brightest innovators in the field of indexing, ETFs, and investment management. The industry's contributions are recognized with seven William F. Sharpe Indexing Achievement Awards. This year's awards were presented on December 7, 2015 in Scottsdale, AZ. The winners were selected by a panel of the world's leading practitioners and researchers in the field of indexing.

About Elkhorn
Founded in 2013 and a strategic partner of Barclays, Elkhorn is redefining the relationship between investment strategy and product structure: designing, sponsoring and distributing innovative, research-based investments solutions. At Elkhorn, research drives design and advisors drive structural decisions. Elkhorn's founder, Ben Fulton, is a recognized leader in the ETF industry, leveraging 30 years of financial services experience to meet the needs of today's investment advisor. To learn more about Elkhorn please visit www.elkhorn.com.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The fund's return may not match the return of the underlying index. The fund invests in equity securities which may be subject to volatile price fluctuations. Because the fund is non-diversified and can invest a greater portion of its assets in securities of individual issuers than a diversified fund, changes in the market value of a single investment could cause greater fluctuations in share price than would occur in a diversified fund. This fund is new and has a limited operating history.

Shares are not individually redeemable and owners of the shares may acquire those shares from the fund and tender those shares for redemption to the fund in Creation Units only, typically consisting of 50,000 Shares.

ALPS Distributors, Inc. is the distributor of Elkhorn's exchange-traded funds.

An investor should consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus containing this and other information, please call 1.800.355.4676. Read the prospectus carefully before investing.

ELK000139 12/23/2016


© Marketwired 2015
Latest news "Companies"
09:35a Celltrion's monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
BU
09:34aDEADLINE ALERT : Kessler Topaz Meltzer & Check, LLP Announces Deadline in Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit
GL
09:32a“Turkey's export capacity is its trump card to feature among the world's top 10 economies”
PU
09:32aJET2 : Bookings surge update - Saturday 18th September »
PU
09:24aAustralia made 'huge mistake' in cancelling submarine deal, says French envoy
RE
09:12aASTRAZENECA : Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
PU
09:07aSHANGHAI ELECTRIC : Ranks 51st on ENR's 2021 Top 250 International Contractors List
AQ
09:07aDAIICHI SANKYO : ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
BU
09:07aASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
BU
09:06aMERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
BU
Latest news "Companies"